Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3)

TetraGraph is a newly developed EMG-based, quantitative, battery-powered neuromuscular monitoring system intended for daily clinical use. The primary aim of this clinical investigation is to examine the applicability (ease of use, equipment need, etc.), repeatability (precision or internal consistency) and performance (signal quality, accuracy of outcome, voltage of stimulation output before and during a stimulus) of the Tetragraph device in patients undergoing elective surgeries requiring neuromuscular blockade.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuromuscular Blockade

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Debrecen

Debrecen, 4032, Hungary

About this study

The TetraGraph will be tested in 50 consenting patients undergiong elective surgeries requiring neuromuscular blockade. The left of right hand of the patients will be randomly studied. After the induction of anesthesia but before the administration of muscle relaxant train-of-four (TOF) stimulation will be started with 30 mA current intensity, 0.2 msec pulse duration at 20 sec intervals. The stimulation will be left to run until extubation. The TetraGraph device will be set not to show measurement results on the screen but save them on the SD card for later analysis. This way TetraGraph will not influence clinical decisions and patient care. During the operations we will record the number of muscle twitches in return to stimulation, the time and dose of muscle relaxant and opioid administration, the time of use of electrocautery and the skin temperature.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18 years or older.
American Society of Anesthesiology (ASA) physical status I-III criteria (Table I).
Subject has provided written informed consent.

Exclusion criteria

Presence of an underlying neuromuscular disease.
Presence of renal or hepatic disease.
Subject has open skin sores in the locations needed for electrode application (forearms).
Patient is taking anti-seizure medication
Patient is taking oral anti-cholinesterase (e.g., therapy for myasthenia gravis)
Magnesium sulfate administration is required

Treatment and study plan

Primary outcomes

Primary performance assessment of TetraGraph device

Time frame: participants will be followed for the duration of their hospital stay, an expected avarage of five days

The primary objective of this study is to provide safety & performance data of the TetraGraph device in anesthetized patients. Performance will be assessed post hoc by analyzing objective EMG data from the SD card and correlating the responses to annotations made during the surgical procedure (e.g., correlating the EMG responses to the time of NMBA or reversal agent administration). No clinical decisions will be made based on any objective measurements made by the TetraGraph. There are no specific timepoints concerning the primary outcome measure of the study.

Secondary outcomes

Secondary performance assessment of TetraGraph Device

Time frame: participants will be followed for the duration of the hospital stay, an expected avarage of 5 days
The secondary outcome measures is a composite of several safety and performance data examined during the operations and the hospital stay:
- Acceptable levels of electrical noise when no stimulus is being applied;
- Ensuring that the stimulus artifact does not obscure the EMG response when a stimulus is applied;
- Appearance of an EMG response at threshold stimulation levels, just sufficient to elicit a palpable twitch response;
- Consistency of the EMG response amplitudes during repeated (ST and TOF) protocols (variability <10%);
- Consistency of EMG response characteristics independent of patient age, gender, or weight;
- Consistency of EMG response characteristics independent whether the right or left arm is stimulated;
- Skin reaction to stimulation or recording electrodes;
- Overall usability of the device for clinicians and operators; collecting recommendations for improving ease of use.
Safety of TetraGraph device

Time frame: participants will be followed for the duration of hospital stay, an expected avarage of 5 days

The safety of Tetragraph device will be assesses by checking the stimulating and recording electrode positions for skin reactions.

Sponsors and collaborators

Lead sponsor

University of Debrecen

Other

Registry information

Acronym: NEAT-3

Important dates

Study start: 2014
Primary completion: 2015
Study completion: 2015
First posted: Sep 16, 2014
Registry last updated: Jan 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed